Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Update

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 1,060,000 shares, an increase of 62.9% from the March 15th total of 650,700 shares. Based on an average trading volume of 331,800 shares, the short-interest ratio is currently 3.2 days.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Reviva Pharmaceuticals in a report on Monday, March 25th.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Armistice Capital LLC raised its position in shares of Reviva Pharmaceuticals by 194.0% in the fourth quarter. Armistice Capital LLC now owns 1,764,000 shares of the company's stock valued at $9,085,000 after buying an additional 1,164,000 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Reviva Pharmaceuticals by 58.3% in the fourth quarter. Vanguard Group Inc. now owns 974,982 shares of the company's stock valued at $5,021,000 after buying an additional 359,050 shares in the last quarter. Colony Group LLC raised its position in Reviva Pharmaceuticals by 66.7% during the second quarter. Colony Group LLC now owns 155,000 shares of the company's stock valued at $908,000 after purchasing an additional 62,000 shares in the last quarter. Geode Capital Management LLC raised its position in Reviva Pharmaceuticals by 3.8% during the second quarter. Geode Capital Management LLC now owns 150,949 shares of the company's stock valued at $885,000 after purchasing an additional 5,519 shares in the last quarter. Finally, EMC Capital Management raised its position in Reviva Pharmaceuticals by 1,294.3% during the third quarter. EMC Capital Management now owns 123,915 shares of the company's stock valued at $613,000 after purchasing an additional 115,028 shares in the last quarter. 63.18% of the stock is currently owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Stock Performance

Shares of NASDAQ RVPH traded down $0.10 during midday trading on Friday, reaching $3.69. The company's stock had a trading volume of 93,949 shares, compared to its average volume of 343,488. Reviva Pharmaceuticals has a fifty-two week low of $2.67 and a fifty-two week high of $9.25. The business's 50 day moving average price is $3.75 and its two-hundred day moving average price is $4.21. The company has a market cap of $103.02 million, a P/E ratio of -2.21 and a beta of -0.02.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.